### **Amendments to the Claims:**

The listing of claims will replace all prior versions and listing of claims in the application:

### Listing of Claims:

Claim 1 (currently amended): A compound, including enantiomers, stereoisomers, rotomers and tautomers of said compound, and pharmaceutically acceptable salts, solvates or derivatives thereof, with said compound having the general structure shown in Formula I:

Formula I

#### wherein:

- X<sup>11</sup> is alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkyl-alkyl, heterocyclyl, heterocyclylalkyl, aryl, alkylaryl, arylalkyl, heteroaryl, alkylheteroaryl, or heteroarylalkyl, with the proviso that X<sup>11</sup> may be additionally optionally substituted with X<sup>12</sup>;
- X<sup>12</sup> is hydroxy, alkoxy, aryloxy, thio, alkylthio, arylthio, amino, alkylamino, arylamino, alkylsulfonyl, arylsulfonyl, alkylsulfonamido, arylsulfonamido, carboxy, carbalkoxy, carboxamido, alkoxycarbonylamino, alkoxycarbonyloxy, alkylureido, arylureido, halogen, cyano, or nitro, with the proviso that said alkyl, alkoxy, and aryl may be additionally optionally substituted with moieties independently selected from X<sup>12</sup>;

W may be present or absent, and if W is present, W is selected form C=O ...C=S, or SO<sub>2</sub>;

Q may be present or absent, and when Q is present, Q Is CH, N, P, (CH<sub>2</sub>)<sub>p</sub>, (CHR)<sub>p</sub>, (CRR')<sub>p</sub>, O, RNR, S, or SO<sub>2</sub>; and when Q is absent, M is also absent, A is directly linked to X;

A is O,  $CH_2$ ,  $(CHR)_p$ ,  $(CHR-CHR')_p$ ,  $(CRR')_p$ , NR, S, SO<sub>2</sub> or a bond;

U is selected from O, N, or CH;

E is CH, N or CR, or a double bond towards A, L or G;

- G may be present or absent, and when G is present, G is  $(CH_2)_p$ ,  $(CHR)_p$ , or  $(CRR')_p$ ; and when G is absent, J is present and E is directly connected to the carbon atom where G was connected to;
- J may be absent or present, and when J is present, J is  $(CH_2)_p$ ,  $(CHR)_p$ , or  $(CRR')_p$ , SO<sub>2</sub>, NH, NR or O; and when J is absent, G is present and L is directly linked to nitrogen;
- L may be present or absent, and when L is present, L is CH, CR, O, S or NR; and when L is absent, then M may be absent or present, and if M is present with L being absent, then M is directly and independently linked to E, and J is directly and independently linked to E;
- M may be present or absent, and when M is present, M is O, NR, S, SO₂, (CH₂)<sub>p</sub>, (CHR)<sub>p</sub>, (CHR-CHR')<sub>p</sub>, or (CRR')<sub>p</sub>;

p is a number from 0 to 6;

R and R' are independently selected from the group consisting of H; C1-C10 alkyl; C2-C10 alkenyl; C3- C8 cycloalkyl; C3-C8 heterocycloalkyl, alkoxy.

aryloxy, alkylthio, arylthio, amino, amido, cyano, nitro; (cycloalkyl)-alkyl and (heterocycloalkyl)alkyl, wherein said cycloalkyl is made of three to eight carbon atoms, and zero to six oxygen, nitrogen, sulfur, or phosphorus atoms, and said alkyl is of one to six carbon atoms; aryl; heteroaryl; alkyl-aryl; and alkyl-heteroaryl; with said alkyl, heteroalkyl, alkenyl, heteroalkenyl, aryl, heteroaryl, cycloalkyl and heterocycloalkyl moieties may be optionally substituted, with said term "substituted" referring to optional and sultable substitution with one or more moieties selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, aralkyl, cycloalkyl, heterocyclic, halogen, hydroxy, thio, alkoxy, aryloxy, alkylthio, arylthlo, amino, amido, cyano, nitro, sulfonamido; and

P<sup>1a</sup>, P<sup>1b</sup>, P<sup>1</sup> and P<sup>3</sup> are independently selected from:

H; C1-C10 straight or branched chain alkyl; C2-C10-straight-or branched chain alkenyl; or C3-C8 cycloalkyl, C3-C8-heterocyclic; (cycloalkyl)alkyl-or (heterocyclyl)alkyl-, wherein said cycloalkyl is made up of 3 to 8 carbon atoms, and zero to 6 oxygen, nitrogen, sulfur, or phosphorus atoms, and said alkyl is of 1 to 6 carbon atoms; aryl, heteroaryl, arylalkyl, or heteroarylalkyl, wherein said alkyl is of 1-to 6 carbon atoms;

wherein said alkyl, alkenyl, cycloalkyl, heterocyclyl; (cycloalkyl)alkyl and (heterocyclyl)alkyl moieties may be optionally substituted with R", and further wherein said P<sup>1a</sup> and P<sup>1b</sup> may optionally be joined to each other to form a spirocyclic or spiroheterocyclic ring, with said spirocyclic or spiroheterocyclic ring containing zero to six oxygen, nitrogen, sulfur, or phosphorus atoms, and may be additionally optionally substituted with R";

R" is hydroxy, alkoxy, aryloxy, thio, alkylthio, arylthio, amino, alkylamino, arylamino, alkylsulfonyl, arylsulfonyl, alkylsulfonamido, arylsulfonamido, carboxy, carbalkoxy, carboxamido, alkoxycarbonylamino, alkoxycarbonyloxy, alkylureido, arylureido, halogen, cyano, or nitro moiety, with the proviso that the alkyl, alkoxy, and aryl may be additionally optionally substituted with moieties independently selected from R";

Z is O. NH or NR":

R<sup>...</sup> is alkyl, alkenyl, alkynyl, cycloalkyl, sycloalkyl alkyl, heterocyclyl, heterocyclyl, heterocyclyl, heterocyclylalkyl, anyl, alkylanyl, anylalkyl, heterocryl, alkylheterocryl, or

heterearylalkyl-moiety, with the provise that R" may be additionally optionally substituted with R=:

- Ar<sup>1</sup> and Ar<sup>2</sup> are independently selected from phenyl; 2-pyridyl, 3-pyridyl, 4-pyridyl or their corresponding N-oxides; 2-thiophenyl; 3-thiophenyl; 2-furanyl; 3-furanyl; 2-pyrrolyl; 3-pyrrolyl; 2-imidazolyl; 3(4)-imidazolyl; 3-(1,2,4-trlazolyl); 5-tetrazolyl; 2-thiazolyl; 4-thiazolyl; 2-oxazolyl; or 4-oxazolyl; either or both of which may be optionally substituted with R<sup>1</sup>;
- R¹ is H, halogen, cyano, nitro, CF₃, Si(alkyl)₃, straight-chain or branched lower alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkyl-alkyl, aryl, alkylaryl, arylalkyl, heteroaryl, hydroxy, alkoxy, aryloxy, alkoxycarbonyloxy, (alkylamino)carbonyloxy, mercapto, alkylthio, arylthio, alkylsulfinyl, heterocyclylsulfinyl, arylsulfinyl, heteroarylsulfinyl, alkylsulfonyl, heterocyclylsulfonyl, arylsulfonyl, heteroarylsulfonyl, alkylcarbonyl, arylcarbonyl, carboxy, alkoxycarbonyl, aryloxycarbonyl, heteroaryloxycarbonyl, alkyaminocarbonyl, arylaminocarbonyl, amino, alkylamino, arylamino, alkylsulfonamide, arylsulfonamide, alkoxycarbonylamino, alkylsulfonamide, or arylureido;

P4 is H, linear or branched alkyl, arylalkyl or aryl; and

R<sup>2</sup> R<sup>2</sup> is H, <del>cyano, CF<sub>3</sub>, straight-chain or branched lower alkyl, alkenyl, alkynyl, cycloalkyl, alkyl-alkyl, aryl, alkylaryl, arylalkyl, heteroaryl, alkyleulfonyl, aryleulfonyl, carboxy, <u>or</u> alkoxycarbonyl, <del>aryloxycarbonyl, alkyaminocarbonyl, or arylaminocarbonyl</del>.</del>

Claim 2 (cancelled).

Claim 3 (currently amended): The compound according to Claim 2, wherein  $\mathbb{R}^2 \mathbb{R}^{2^i}$  is H, U is N and  $\mathbb{P}^4$  is H.

<u>Claim 4</u> (original): The compound according to Claim 1, wherein Ar<sup>1</sup> and Ar<sup>2</sup> are independently selected from the group consisting of phenyl, 2-thiophenyl, 2-furanyl, 3-furanyl, 3(4)-imidazolyl, 3-(1,2,4-triazolyl), 5-tetrazolyl, or 2-thiazolyl.

<u>Claim 5</u> (original): The compound according to Claim 4, wherein Ar<sup>2</sup> is phenyl and Ar<sup>1</sup> is selected from the group consisting of 3-(1,2,4-triazolyl),5-tetrazolyl, or 2-thiazolyl and U is N and P<sup>4</sup> is H..

Claim 6 (original): The compound according to Claim 1 or claim 4, wherein  $R^1$  is H,  $CF_3$ ,  $CH_3$ , alkyl or alkenyl.

<u>Claim 7</u> (original): The compound according to Claim 4, wherein  $R^1$  is H,  $CF_3$ ,  $CH_3$ , alkyl or alkenyl.

Claim 8 (original): The compound according to Claim 1, wherein P1' is H or CH3.

<u>Claim 9</u> (original): The compound according to Claim 1, wherein P<sup>1'</sup> is H such that P<sup>1'</sup> and the adjacent nitrogen and carbonyl moieties correspond to the residuum of a glycine unit.

<u>Claim 10</u> (currently amended): The compound of Claim 4, wherein P<sup>1a</sup> and P<sup>1b</sup> are independently selected from the group consisting of the following moieties:

Claim 11 (currently amended): The compound according to Claim 4, wherein P<sup>3</sup> is selected from the group consisting of:

herein wherein R31 = OH or O-alkyl.

Claim 12 (currently amended): The compound of Claim 4, wherein P<sup>3</sup> is selected from the group consisting of the following moleties:

wherein  $R^{31} = OH$  or O-Alkyl.

Claim 13: cancelled.

Claim 14: cancelled.

Claim 15 (original): The compound of Claim 1, wherein the moiety:

Claim 16: cancelled.

<u>Claim 17</u> (original): The compound according to Claim 1, wherein said compound is selected from the group consisting of compounds having the structural formulae:

wherein P<sup>3</sup> is an isopropyl, tertiary butyl, cyclopentyl, or cyclohexyl moiety.

Claim 18 (previously amended): A pharmaceutical composition comprising as an active ingredient a compound of Claim 1 and a pharmaceutically acceptable carrier.

Claim 19-20: (cancelled).

Claim 21 (previously amended): The pharmaceutical composition of Claim 18, additionally containing an antiviral agent.

<u>Claim 22</u> (previously amended): The pharmaceutical composition of Claim 21, additionally containing an interferon.

<u>Claim 23</u> (original): The pharmaceutical composition of Claim 22, wherein said antiviral agent is ribavirin and said interferon is α-interferon.

Claims 24-94: (Cancelled).

Claim 95 (New claim): A compound selected from:

Claim 96 (New claim): A method of treating disorders associated with the HCV, said method comprising administering to a patient in need of such treatment a pharmaceutical composition which comprises therapeutically effective amounts of a compound of claim 1.

Claim 97 (New claim): The method of claim 96, wherein said administration is subcutaneous.

# This Page is Inserted by IFW Indexing and Scanning Operations and is not part of the Official Record

## **BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

befects in the images include but are not limited to the items checked:
□ BLACK BORDERS
☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
☐ FADED TEXT OR DRAWING
☐ BLURRED OR ILLEGIBLE TEXT OR DRAWING
☐ SKEWED/SLANTED IMAGES
COLOR OR BLACK AND WHITE PHOTOGRAPHS
GRAY SCALE DOCUMENTS
LINES OR MARKS ON ORIGINAL DOCUMENT
☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
□ other:

## IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.